Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

Several other analysts also recently issued reports on SYN. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, August 9th. William Blair reiterated an “outperform” rating and issued a $5.00 price target on shares of Synthetic Biologics in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $3.92.

Synthetic Biologics (NYSEMKT SYN) traded down 1.32% on Friday, reaching $0.75. The company had a trading volume of 1,180,315 shares. The stock’s 50-day moving average price is $0.58 and its 200 day moving average price is $0.61. Synthetic Biologics has a 52-week low of $0.41 and a 52-week high of $1.90. The firm’s market capitalization is $96.19 million.

Synthetic Biologics (NYSEMKT:SYN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. On average, equities analysts anticipate that Synthetic Biologics will post ($0.17) earnings per share for the current fiscal year.

WARNING: “Synthetic Biologics Inc (SYN) Downgraded by ValuEngine” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/02/synthetic-biologics-inc-syn-downgraded-by-valuengine.html.

Several hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its stake in shares of Synthetic Biologics by 8,102.7% in the second quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock valued at $639,000 after buying an additional 1,115,343 shares in the last quarter. Norges Bank acquired a new stake in shares of Synthetic Biologics during the fourth quarter valued at $356,000. LMR Partners LLP acquired a new stake in shares of Synthetic Biologics during the second quarter valued at $194,000. Bank of New York Mellon Corp increased its stake in shares of Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares in the last quarter.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.